MY184343A - Compounds and compositions for the treatment of cancer - Google Patents

Compounds and compositions for the treatment of cancer

Info

Publication number
MY184343A
MY184343A MYPI2017000606A MYPI2017000606A MY184343A MY 184343 A MY184343 A MY 184343A MY PI2017000606 A MYPI2017000606 A MY PI2017000606A MY PI2017000606 A MYPI2017000606 A MY PI2017000606A MY 184343 A MY184343 A MY 184343A
Authority
MY
Malaysia
Prior art keywords
formula
compounds
cancer
treatment
compositions
Prior art date
Application number
MYPI2017000606A
Other languages
English (en)
Inventor
Lyne Gagnon
Brigitte Grouix
Lilianne Geerts
Laurin Pierre
Christopher Penney
Boulos Zacharie
Original Assignee
Prometic Pharma Smt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometic Pharma Smt Ltd filed Critical Prometic Pharma Smt Ltd
Publication of MY184343A publication Critical patent/MY184343A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C07C57/32—Phenylacetic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/78—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C217/80—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings
    • C07C217/82—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring
    • C07C217/84—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/18—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/42—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/46—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/46—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid
    • C07C57/48—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid having unsaturation outside the aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/52—Unsaturated compounds containing hydroxy or O-metal groups a hydroxy or O-metal group being bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/54—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/84—Unsaturated compounds containing keto groups containing six membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C62/18—Saturated compounds containing keto groups
    • C07C62/20—Saturated compounds containing keto groups with a saturated six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/04—Monocyclic monocarboxylic acids
    • C07C63/06—Benzoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/04—Monocyclic monocarboxylic acids
    • C07C63/06—Benzoic acid
    • C07C63/08—Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MYPI2017000606A 2010-10-27 2011-10-26 Compounds and compositions for the treatment of cancer MY184343A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40706910P 2010-10-27 2010-10-27

Publications (1)

Publication Number Publication Date
MY184343A true MY184343A (en) 2021-04-01

Family

ID=46515034

Family Applications (2)

Application Number Title Priority Date Filing Date
MYPI2017000606A MY184343A (en) 2010-10-27 2011-10-26 Compounds and compositions for the treatment of cancer
MYPI2013001522A MY162420A (en) 2010-10-27 2011-10-26 Compounds and compositions for the treatment of cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
MYPI2013001522A MY162420A (en) 2010-10-27 2011-10-26 Compounds and compositions for the treatment of cancer

Country Status (24)

Country Link
US (2) US9114118B2 (enExample)
EP (2) EP2632452B1 (enExample)
JP (2) JP6007186B2 (enExample)
KR (2) KR101821646B1 (enExample)
CN (2) CN105997967B (enExample)
AU (2) AU2011356583C1 (enExample)
BR (1) BR112013010507A2 (enExample)
CA (1) CA2816093C (enExample)
CL (1) CL2013001152A1 (enExample)
DK (2) DK3443957T3 (enExample)
EA (2) EA035494B1 (enExample)
ES (2) ES2703257T3 (enExample)
IL (2) IL225599A (enExample)
MX (2) MX381345B (enExample)
MY (2) MY184343A (enExample)
NZ (1) NZ610851A (enExample)
PH (2) PH12013500766B1 (enExample)
PL (2) PL3443957T3 (enExample)
PT (2) PT3443957T (enExample)
SG (2) SG10201807622WA (enExample)
TR (1) TR201819987T4 (enExample)
TW (2) TWI620563B (enExample)
WO (1) WO2012097427A1 (enExample)
ZA (1) ZA201303035B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI620563B (zh) * 2010-10-27 2018-04-11 波麥堤克藥學Ｓｍｔ有限公司 用於治療癌症的化合物及組成物
TWI689489B (zh) 2013-03-15 2020-04-01 英商邊緣生物科技有限公司 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物
RU2560702C1 (ru) * 2014-06-05 2015-08-20 Общество с ограниченной ответственностью "Научно-производственный центр "Амфион" (ООО "НПЦ "Амфион") Фармацевтическая композиция для применения в онкологии
RU2709205C2 (ru) 2014-10-10 2019-12-17 Прометик Фарма Смт Лимитед Замещенные ароматические соединения и фармацевтические композиции для предотвращения и лечения остеопороза
CA2963358C (en) * 2014-10-10 2023-03-07 Prometic Biosciences Inc. Phenylketone carboxylate compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis
US10391073B2 (en) * 2014-11-12 2019-08-27 Prometic Pharma Smt Limited Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration
CN106267213A (zh) * 2015-05-27 2017-01-04 聊城市奥润生物医药科技有限公司 环二核苷酸cGAMP在治疗肿瘤联合用药中的应用
WO2019023388A1 (en) 2017-07-25 2019-01-31 Taris Biomedical Llc METHODS OF TREATING TUMOR METASTASIS
CA3081839A1 (en) 2017-11-08 2019-05-16 Taris Biomedical Llc Methods of treatment and maintenance therapy for bladder cancer using gemcitabine
JP2022510436A (ja) * 2018-12-05 2022-01-26 リミナル・バイオサイエンシーズ・リミテッド アルストレーム症候群の治療における２－（３－ペンチルフェニル）酢酸ナトリウムの使用
US11246945B2 (en) 2019-06-07 2022-02-15 National Defense Medical Center Cisplatin-loaded microbubbles, pharmaceutical composition for treatment of cancer, method for preparing pharmaceutical compositions and method for treating cancer
MX2022000570A (es) 2019-07-26 2022-03-11 Espervita Therapeutics Inc Acidos mono- y dicarboxilicos hidrocarbonados de cadena larga funcionalizados y su uso para la prevencion o el tratamiento de enfermedad.
US20240043372A1 (en) * 2020-10-06 2024-02-08 Pharmaceutique Ingenew Inc. Substituted aromatic compounds and pharmaceutical compositions thereof
KR20230152007A (ko) 2021-01-25 2023-11-02 에스퍼비타 테라퓨틱스, 인크. 작용화된 장쇄 카복실산, 및 질환의 치료를 위한 이의 용도
CN114436822B (zh) * 2022-01-12 2024-04-16 厦门稀土材料研究所 一枝蒿酮酸和生物碱复盐及其制备方法和用途
AU2024239546A1 (en) * 2023-03-22 2025-10-02 Uti Limited Partnership Hydroxyphenyl propanoate compounds for tumour immunotherapy, compositions and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0268907A3 (en) 1986-11-19 1990-03-21 Carl Richard Thornfeldt Treatment of disease conditions relating to hyperactive organelles
US5605930A (en) * 1991-10-21 1997-02-25 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for treating and preventing pathologies including cancer
ITMI20012434A1 (it) 2001-11-20 2003-05-20 Dompe Spa Acidi 2-aril-propionici e composizioni farmaceutiche che li contengono
CN1169768C (zh) * 2002-04-26 2004-10-06 中国科学院上海有机化学研究所 （4－炔基）－芳香酮酸类化合物、合成方法及应用
CA2506897A1 (en) * 2002-12-27 2004-07-15 Tibotec Bvba Fluorogenic enzyme substrates and methods of preparation
WO2005010202A2 (en) * 2003-07-16 2005-02-03 Ligand Pharmacueticals Incorporated PHENYL ACETIC ACID DERIVATIVES AS HEPATOCYTE NUCLEAR FACTOR 4α (HNF-4α) MODULATOR COMPOUNDS
WO2005009104A2 (en) * 2003-07-16 2005-02-03 Ligand Pharmacueticals Incorporated Benzoic and phenyl acetic acid derivatives as hnf-4 modulators
US8198328B2 (en) * 2004-01-21 2012-06-12 New York University Treatment of cancer using benzoic acid derivatives
JP2010502586A (ja) 2006-09-01 2010-01-28 ピラマル・ライフ・サイエンシーズ・リミテッド コーヒー酸と誘導体の抗ガン用途
WO2008112368A2 (en) * 2007-02-08 2008-09-18 Emisphere Technologies, Inc. Phenylalkylcarboxylic acid delivery agents
WO2009055932A1 (en) 2007-11-02 2009-05-07 Prometic Biosciences Inc. Substituted phenylpropionic acids as stimulators of hematopoiesis and erythropoiesis
RU2519215C2 (ru) * 2007-11-02 2014-06-10 Прометик Байосайенсиз Инк. Жирные кислоты и глицериды со средней длиной цепи в качестве нефропротективных средств
WO2009076761A1 (en) * 2007-12-19 2009-06-25 Prometic Biosciences Inc. Medium-chain length fatty acids, salts and triglycerides in combination with gemcitabine for treatment of pancreatic cancer
TWI485134B (zh) * 2009-05-04 2015-05-21 波麥堤克生化科學公司 取代的芳族化合物及其藥學用途
JP5844251B2 (ja) * 2009-05-04 2016-01-13 プロメティック・バイオサイエンシーズ・インコーポレイテッドＰｒｏＭｅｔｉｃ ＢｉｏＳｃｉｅｎｃｅｓ Ｉｎｃ． ３−ペンチルフェニル酢酸の塩およびその薬学的使用
TWI620563B (zh) * 2010-10-27 2018-04-11 波麥堤克藥學Ｓｍｔ有限公司 用於治療癌症的化合物及組成物

Also Published As

Publication number Publication date
EP2632452A4 (en) 2014-05-07
EP2632452B1 (en) 2018-09-26
US20150313856A1 (en) 2015-11-05
PT2632452T (pt) 2019-01-10
IL251083A0 (en) 2017-04-30
DK3443957T3 (da) 2020-12-21
AU2016201556A1 (en) 2016-04-14
AU2011356583C1 (en) 2016-03-17
US9114118B2 (en) 2015-08-25
IL225599A0 (en) 2013-06-27
TW201305097A (zh) 2013-02-01
KR101943280B1 (ko) 2019-01-28
MY162420A (en) 2017-06-15
PT3443957T (pt) 2020-12-18
NZ610851A (en) 2015-05-29
EP2632452A1 (en) 2013-09-04
US9439882B2 (en) 2016-09-13
TWI620563B (zh) 2018-04-11
PH12013500766A1 (en) 2013-06-24
JP2016188247A (ja) 2016-11-04
JP2013544799A (ja) 2013-12-19
DK2632452T3 (en) 2019-01-21
WO2012097427A1 (en) 2012-07-26
SG10201807622WA (en) 2018-10-30
TW201717928A (zh) 2017-06-01
IL251083B (en) 2018-07-31
CA2816093A1 (en) 2012-07-26
US20130217645A1 (en) 2013-08-22
EA035494B1 (ru) 2020-06-25
TWI578983B (zh) 2017-04-21
PL2632452T3 (pl) 2019-03-29
KR101821646B1 (ko) 2018-01-25
EP3443957B1 (en) 2020-11-25
TR201819987T4 (tr) 2019-01-21
PH12016502324B1 (en) 2023-10-11
JP6371344B2 (ja) 2018-08-08
KR20130132448A (ko) 2013-12-04
CN103347509A (zh) 2013-10-09
CL2013001152A1 (es) 2014-01-10
AU2016201556B2 (en) 2017-09-14
PH12013500766B1 (en) 2017-09-29
MX365807B (es) 2019-06-14
CN103347509B (zh) 2016-06-08
JP6007186B2 (ja) 2016-10-12
CN105997967B (zh) 2019-08-23
IL225599A (en) 2017-05-29
MX2019007010A (es) 2019-09-06
BR112013010507A2 (pt) 2016-08-02
EP3443957A1 (en) 2019-02-20
SG189538A1 (en) 2013-06-28
PH12016502324A1 (en) 2019-07-15
MX2013004832A (es) 2013-05-22
ES2703257T3 (es) 2019-03-07
MX381345B (es) 2025-03-12
KR20180011332A (ko) 2018-01-31
ES2837599T3 (es) 2021-06-30
CN105997967A (zh) 2016-10-12
ZA201303035B (en) 2014-06-25
HK1189836A1 (zh) 2014-06-20
PL3443957T3 (pl) 2021-05-04
EA030038B1 (ru) 2018-06-29
EA201791585A1 (ru) 2018-05-31
AU2011356583B2 (en) 2015-12-24
CA2816093C (en) 2020-12-01
AU2011356583A1 (en) 2013-05-09
EA201370103A1 (ru) 2013-12-30

Similar Documents

Publication Publication Date Title
PH12016502324A1 (en) Compounds and compositions for the treatment of cancer
NZ598890A (en) Inhibitors of iap
MX2011011661A (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750.
MY188911A (en) Methods of treating bladder cancer
CL2011000504A1 (es) Compuestos derivados de piridin-4-il-tiazol-2il-amida 2-amida-pirrolidin-1,2-dicarboxilico, inhibidores de quinasa de fosfatidil-inositol-3; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de un medicamento para el tratamiento del cancer.
MA34064B1 (fr) Compose heterocyclique
NZ718826A (en) Pyrrolobenzodiazepines and conjugates thereof
TN2010000167A1 (en) Organic compounds
PH12014501542A1 (en) Substituted pyrrolidine -2- carboxamides
MX2010013682A (es) Derivados de 2,4-diamino-l,3,5-triazina triciclicos utiles para el tratamiento del cancer y trastornos mieloproliferativos.
MY177344A (en) Compounds and their methods of use
GEP201706691B (en) Substituted phthalazin-1 (2h)-one derivatives as selecti- ve inhibitors of poly (adp-ribose) polymerase-1
MX2013014898A (es) Antagonistas de trpv4.
EA201390008A1 (ru) Новые ариламидные производные, обладающие антиандрогенными свойствами
MY152018A (en) Indole derivatives as anticancer agents
WO2010027424A3 (en) 9-substituted phenanthrene based tylophorine derivatives
GEP201706741B (en) Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
WO2013040227A3 (en) Therapeutic compounds
MY178583A (en) Hydantoin derivative
TW200800993A (en) Organic compounds
MX2012007253A (es) Derivados triciclicos y sus usos y composiciones farmaceuticas.
MX2015012600A (es) Compuestos de tetrahidroisoquinolina-2-il-(quinazolina-4-il) metanona como inhibidores del crecimiento de células cancerígenas.
MX341492B (es) Nuevas formas solidas de 1,1-dioxo-4-tiomorfolinil)-[6-[[3(4-fluor ofenil)-5-metil-4-isoxazolil]metoxi]-3-piridinil]-metanona.
AR077483A1 (es) Sal de citrato del 9e-15-(2-pirrolidin -1-il-etoxi)-7,12,25-trioxa-19-21,24-triaza-tetraciclo (18-3.1.1(2,5).1(14,18) hexacosa-1 (24),2,4,9,14,16,18 (26),20,22- nonaeno
GEP20125545B (en) New chromene compounds, a process for their preparation and pharmaceutical compositions containing them